Juliana Doblas Massaro

Dr. Juliana Doblas Massaro


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
JMJuliana Doblas Massaro
Juliana Doblas Massaro
CPClaudia Danella Polli
Claudia Danella Polli
MSMatheus Costa e Silva
Matheus Costa e Silva
CACinthia Caroline Alves
Cinthia Caroline Alves
GPGeraldo A Passos
Geraldo A Passos
EDEduardo A. Donadi
Eduardo A. Donadi

1 December 2018 in Molecular Immunology
Verified
Journal Article
Closed access
PSPaulin Sonon
Paulin Sonon
ISIbrahim Sadissou
Ibrahim Sadissou
LTLéonidas Tokplonou
Léonidas Tokplonou
KMKuumaaté K.G. M'PO
Kuumaaté K.G. M'PO
SGSonya S.C. Glitho
Sonya S.C. Glitho
EDEduardo A. Donadi
Eduardo A. Donadi

Verified
Journal Article
Open access
PDF file
BBBruna C. Bertol
Bruna C. Bertol
JMJuliana Doblas Massaro
Juliana Doblas Massaro
GDGuilherme Debortoli
Guilherme Debortoli
APAndre Luiz Pinto
Andre Luiz Pinto
JAJéssica N. G. de Araújo
Jéssica N. G. de Araújo
EDEduardo A. Donadi
Eduardo A. Donadi
As BRAF, TERT, HLA-G, and microRNAs have been individually associated with papillary thyroid carcinoma (PTC), we aimed to evaluate the individual and collaborative role of these markers in PTC in the same patient cohort. HLA-G and BRAF tumor expression was evaluated by immunohistochemistry. Using molecular methods, BRAFV600E and TERT promoter mutations were evaluated in thyroid fine needle aspirates. MicroRNA tumor profiling was investigated using massively parallel sequencing. We observed strong HLA-G (67.96%) while BRAF (62.43%) staining was observed in PTC specimens. BRAF overexpression was associated with poor response to therapy. The BRAFV600E (52.9%) and TERTC228T (13%) mutations were associated with extrathyroidal extension, advanced-age, and advanced-stage cancer. The TERT rs2853669 CC+TC genotypes (38%) were overrepresented in metastatic tumors. Nine modulated microRNAs targeting the BRAF, TERT, and/or HLA-G genes were observed in PTC and involved with cancer-related signaling pathways. The markers were individually associated with PTC features, emphasizing the synergistic effect of BRAFV600E and TERTC228T; however, their collaborative role on PTC outcome was not fully demonstrated. The differentially expressed miRNAs targeting the BRAF and/or HLA-G genes may explain their increased expression in the tumor milieu.